512 related articles for article (PubMed ID: 24576547)
21. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; Morandi E; van Eickels M; Cohen A
Am Heart J; 2015 Apr; 169(4):464-71.e2. PubMed ID: 25819852
[TBL] [Abstract][Full Text] [Related]
22. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter.
Xavier Scheuermeyer F; Grafstein E; Stenstrom R; Innes G; Poureslami I; Sighary M
Acad Emerg Med; 2010 Apr; 17(4):408-15. PubMed ID: 20370780
[TBL] [Abstract][Full Text] [Related]
23. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Coleman CM; Khalaf S; Mould S; Wazni O; Kanj M; Saliba W; Cantillon D
Pacing Clin Electrophysiol; 2015 Jun; 38(6):731-7. PubMed ID: 25721150
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
[TBL] [Abstract][Full Text] [Related]
25. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
26. Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Naccarelli GV; Gonzalez MD
J Interv Card Electrophysiol; 2013 Jan; 36(1):3-4. PubMed ID: 23054126
[No Abstract] [Full Text] [Related]
27. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
28. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
[TBL] [Abstract][Full Text] [Related]
29. New oral anticoagulants: will they replace warfarin?
Little JW
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May; 113(5):575-80. PubMed ID: 22668618
[TBL] [Abstract][Full Text] [Related]
30. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion.
Roijer A; Eskilsson J; Olsson B
Eur Heart J; 2000 May; 21(10):837-47. PubMed ID: 10781356
[TBL] [Abstract][Full Text] [Related]
31. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Zylla MM; Pohlmeier M; Hess A; Mereles D; Kieser M; Bruckner T; Scholz E; Zitron E; Schweizer PA; Katus HA; Thomas D
Am J Cardiol; 2015 Mar; 115(5):635-40. PubMed ID: 25591898
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
34. Elective Cardioversion in the Era of Novel Oral Anticoagulants - Does a Nurse Administered Verbal Questionnaire for Compliance Negate the Need for Routine Transoesophageal Echocardiography?
Rowe MK; Lollback N; Slater L; Hill J; Gould PA; Kaye GC
Heart Lung Circ; 2018 Aug; 27(8):989-994. PubMed ID: 28966115
[TBL] [Abstract][Full Text] [Related]
35. New insights into the predictors of left atrial stunning after successful direct-current cardioversion of atrial fibrillation and flutter.
Melduni RM; Malouf JF; Chandrasekaran K; Bruce CJ; White RD; Law KK; Al Atawi FO; Somers VK; Gersh BJ; Hodge DO; Friedman PA; Seward JB; Ammash NM
J Am Soc Echocardiogr; 2008 Jul; 21(7):848-54. PubMed ID: 18222642
[TBL] [Abstract][Full Text] [Related]
36. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Baglin T
Br J Haematol; 2013 Oct; 163(2):160-7. PubMed ID: 23937286
[TBL] [Abstract][Full Text] [Related]
38. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Stepanyan G; Badhwar N; Lee RJ; Marcus GM; Lee BK; Tseng ZH; Vedantham V; Olgin J; Scheinman M; Gerstenfeld EP
J Interv Card Electrophysiol; 2014 Jun; 40(1):33-8. PubMed ID: 24643666
[TBL] [Abstract][Full Text] [Related]
39. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Kovács T
Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
[TBL] [Abstract][Full Text] [Related]
40. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
